mercredi 6 septembre 2017

Onco Actu du 6 septembre 2017

1. Biologie

Plot a course through the genome [Nature]

2.8 Etiologie - Contraceptifs, THS

Vaginal estrogen not tied to cancer or heart disease risks [Reuters]

3.3 Prévention - Vaccins

A Prize for Cancer Prevention [Cell]

Lasker Prizes go to Planned Parenthood and Developers of HPV Vaccine [NY Times]

4.1 Dép., diag. & prono. - Prostate

New Analysis Confirms Suspected Bias of Large U.S. Prostate Screening Study [ACS]

4.2 Dép., diag. & prono. - Génome

Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing [Myriad]

5.1 Traitements - Pré-clinique

Zika virus selectively infects and kills glioblastoma cells in mice [NIH]

Zika virus shrinks brain tumours in lab tests [Cancer Research UK]

Gut Microbes May Promote Immune Responses Against Colorectal Cancer [AACR]

Zika virus used to treat aggressive brain cancer [BBC News]

5.10 Traitements - Essais

Crizotinib Shows Promise for Childhood Cancers [NCI]

5.12.2 Immunothérapies - CAR-T

Patient’s Immune Status Associated with Outcome Following Third-generation CAR T–Cell Therapy [AACR]

5.12.3 Immunothérapies-combinaisons

Inactivated Vaccinia Virus Safe and Effective Against Advanced Cancers Alone or in Combination with Immune Checkpoint Inhibitors [AACR]

5.12.6 Immunothérapies - AMM

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer [Merck]

5.2.2 Pharma - Fusions & Acquisitions

Here’s the inside account of Gilead’s 11-week sprint to its $12B Kite buyout [EndPoints]

5.2.3 Pharma - économie

ASCO spotlight presaged two more biotech IPOs angling for $215M [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Reporting side effects of medicines [EMA]

5.4 Traitements - Economie

Novartis charged much more in the U.S. for some drugs than in other countries [STAT]

5.6.4 ESMO - Poumon

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer [Roche]

ESMO 2017 Press Release: Alectinib: ALEX and ALUR Trials Show CNS Benefit in NSCLC [ESMO]

Roche lung cancer drug Alecensa slashes brain risk in tests [Reuters]

6. Lutte contre les cancers

Written Treatment Summaries Are Crucial to Meeting Needs for Information on Recurrence, Fertility, and Late Treatment Effects in Adolescent and Young Adult Cancer Survivors [ESMO]

Young cancer patients advocate for improved care [BMJ Blogs]

6.10.1 Politiques (USA)

Budget battle looms for US science programmes [Nature]

6.6 Publications

Journal policies that encourage data sharing prove extremely effective [LSE Impact Blog]